{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:08:40Z","timestamp":1776276520541,"version":"3.50.1"},"reference-count":112,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2021,11,2]]},"DOI":"10.1080\/13543784.2021.2010187","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T16:32:15Z","timestamp":1638203535000},"page":"1109-1124","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials"],"prefix":"10.1080","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-7532","authenticated-orcid":false,"given":"Leticia","family":"Garcia-Montoya","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1002\/art.41042"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14956.1"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04970-3"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"cit0006","volume-title":"Tumor necrosis factor inhibitors. statpearls","author":"Gerriets V"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6248"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-019-0057-8"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380407"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.037465"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(93)90106-L"},{"key":"cit0014","unstructured":"European Medicines Agency. Infliximab: summary of product characteristics. [Cited 2021 Apr 8]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.6.428"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1002\/art.511"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1002\/art.11104"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025130"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh584"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075879"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.08.005"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken207"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem166"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020503"},{"issue":"4","key":"cit0027","first-page":"997","volume":"26","author":"Spoorenberg A","year":"1999","journal-title":"J Rheumatol"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1002\/art.21790"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1002\/art.10883"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei046"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"cit0032","unstructured":"European Medicines Agency. Etanercept: summary of product characteristics. [cited 2021 Apr 16. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enbrel"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1002\/art.20241"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1002\/art.20790"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh475"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1002\/art.21588"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1186\/ar4244"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1002\/art.40786"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139667"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.147033"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu263"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.08.005"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140056"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20987700"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1002\/art.23471"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"cit0050","unstructured":"European Medicines Agency. Adalimumab: summary of product characteristics. [cited 2021 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1002\/art.23606"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu438"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1002\/art.21563"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1002\/art.39434"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0239-z"},{"key":"cit0057","unstructured":"European Medicines Agency. Certolizumab: summary of product characteristics. [cited 2021 May 7]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cimzia-epar-product-information_en.pdf"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex174"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212377"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.12304"},{"key":"cit0064","unstructured":"European Medicines Agency. Golimumab: summary of product characteristics. [cited 2021 May 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simponi-epar-product-information_en.pdf"},{"key":"cit0065","unstructured":"US Food and drug administration. Simponi: highlights of prescribing information. [cited 2021 Sept 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125433s030s031lbl.pdf"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154799"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203075"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200308"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170487"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180718"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210931"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001161"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180312"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197"},{"issue":"6","key":"cit0077","first-page":"1132","volume":"38","author":"Choi EY","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203582"},{"issue":"4","key":"cit0079","first-page":"Cd011535","volume":"4","author":"Sbidian E","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1002\/art.21233"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0489-2"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619883566"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14030"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00432-z"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00259-8"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex269"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15152"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175207"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2009-5"},{"key":"cit0091","first-page":"1","volume":"2","author":"Gehin JE","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex474"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001047"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033472"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211544"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1002\/art.33465"},{"issue":"10","key":"cit0097","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"Haroon N","year":"2013","journal-title":"Arthritis Rheumatism"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.22374\/1710-6222.25.1.5"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"cit0101","first-page":"27","author":"Deodhar A","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"cit0102","unstructured":"European Medicines Agency. Upadacitinib: summary of product characteristics. [cited 2021 Sept 6]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf"},{"issue":"1","key":"cit0103","first-page":"50","volume":"36","author":"Baraliakos X","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210023"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207544"},{"key":"cit0107","unstructured":"European Medicines Agency. Secukinumab: summary of product characteristics. [cited 2021 Sept 8]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf"},{"key":"cit0108","unstructured":"European Medicines Agency. Ixekizumab: summary of product characteristics. [cited 2021 Sept 8]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf"},{"key":"cit0109","first-page":"7","author":"Wei JC","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216980"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.4.353"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2021.2010187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T09:22:24Z","timestamp":1699867344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2021.2010187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":112,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,2]]}},"alternative-id":["10.1080\/13543784.2021.2010187"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2021.2010187","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}